Cargando…
Reversed papilledema in an MPS VI patient with galsulfase (Naglazyme(®)) therapy
MPS VI (mucopolysaccharidosis VI, known as Maroteaux–Lamy syndrome) is a multi-systemic inherited disease, resulting from a deficiency of N-acetylgalactosamine-4-sulfatase, causing accumulation of the glycosaminoglycan (GAG) dermatan sulfate in all tissues. It is one of almost 50 lysosomal storage d...
Autores principales: | Koseoglu, Selim T., Harmatz, Paul, Turbeville, Sean, Nicely, Helen |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714452/ https://www.ncbi.nlm.nih.gov/pubmed/18418554 http://dx.doi.org/10.1007/s10792-008-9213-7 |
Ejemplares similares
-
Galsulfase (Naglazyme®) therapy in infants with mucopolysaccharidosis VI
por: Harmatz, Paul R., et al.
Publicado: (2013) -
Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme(®)) therapy
por: Braunlin, E., et al.
Publicado: (2012) -
Mucopolysaccharidosis VI
por: Valayannopoulos, Vassili, et al.
Publicado: (2010) -
Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase
por: Brands, Marion M, et al.
Publicado: (2013) -
Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series
por: Lin, Hsiang-Yu, et al.
Publicado: (2016)